An international collaboration led by Prof. Lih-Chu Chiou, College of Medicine, National Taiwan University, has identified a novel promising drug candidate, the α6-containing GABAA receptor-selective positive allosteric modulator, for the treatment of migraine, trigeminal pain and neuropsychiatric disorders (schizophrenia and Tourette syndrome).

候選藥物在動物模式中有效地抑制偏頭痛、三叉神經痛以及精神疾病的症狀，而且沒有傳統苯二氮卓類(benzodiazepine)藥物的副作用(如嗜睡，遺忘，肌肉無力，耐受性和成癮性)，加上具良好藥物動態學性質，極具潛力發展成上述疾病之首創新藥。

The candidate compound has promising safety pharmacology and pharmacokinetics and may emerge as novel drug candidate for above diseases. It is ready to enter pre-clinical IND-enabling studies. If successfully approved in the future, it would provide the first-in-class and safe medicinal therapy to the patients inflicted with the mentioned diseases.